If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== 2010 census === The 2010 United States census counted 8,573 people, 3,002 households, and 2,318 families in the borough. The population density was 4,154.5 per square mile (1,604.1/km2). There were 3,114 housing units at an average density of 1,509.0 per square mile (582.6/km2). The racial makeup was 68.95% (5,911) White, 0.73% (63) Black or African American, 0.03% (3) Native American, 27.64% (2,370) Asian, 0.01% (1) Pacific Islander, 1.07% (92) from other races, and 1.55% (133) from two or more races. Hispanic or Latino of any race were 6.26% (537) of the population. Korean Americans accounted for 17.8% of the population. Of the 3,002 households, 40.5% had children under the age of 18; 66.2% were married couples living together; 7.9% had a female householder with no husband present and 22.8% were non-families. Of all households, 21.1% were made up of individuals and 15.4% had someone living alone who was 65 years of age or older. The average household size was 2.84 and the average family size was 3.32. Same-sex couples headed 7 households in 2010, an increase from the 5 counted in 2000. 26.8% of the population were under the age of 18, 5.4% from 18 to 24, 20.6% from 25 to 44, 29.8% from 45 to 64, and 17.4% who were 65 years of age or older. The median age was 43.7 years. For every 100 females, the population had 88.6 males. For every 100 females ages 18 and older there were 85.7 males.
== History == Etoperidone was discovered by scientists at Angelini, who also discovered trazodone. Its development names have included ST-1191 and McN-A-2673-11. The INNTooltip International Nonproprietary Name etoperidone was proposed in 1976 and recommended in 1977. The drug was given brand names in Spain (Centren (Esteve) and Depraser (Lepori)) and Italy (Staff (Sigma Tau)) and was also given the brand names Axiomin and Etonin, but it is not entirely clear if it was actually marketed; the Pharmaceutical Manufacturing Encyclopedia provides no dates for commercial introduction. According to Micromedex's Index Nominum: International Drug Directory, etoperidone was indeed previously marketed in Spain and Italy.
== Drug history == The discovery of paclitaxel began in 1962 as a result of a NCI-funded screening program. A number of years later it was isolated from the bark of the Pacific yew, Taxus brevifolia, hence its name "taxol". The discovery was made by Monroe E. Wall and Mansukh C. Wani at the Research Triangle Institute, Research Triangle Park, North Carolina, in 1971. These scientists isolated the natural product from the bark of the Pacific yew tree, determined its structure and named it "taxol", and arranged for its first biological testing. The compound was then developed commercially by BMS, who had the generic name assigned as "paclitaxel".
=== Regulatory gaps and the absence of statutory safeguards === A central criticism of UK AI policy is that its light-touch, pro-innovation regulatory stance leaves the public inadequately protected from AI-related harms. The Ada Lovelace Institute, an independent research body, has argued that the UK "lacks a comprehensive legal framework to govern AI systems" and that many harmful AI capabilities "arise during the design and development of AI systems — where few rules apply and few regulators have oversight". The Institute has called for a statutory AI Bill that mandates pre-deployment testing for general-purpose AI systems, empowers regulators to withdraw unsafe models from the UK market, and requires developers to disclose known risks, environmental impacts, and mitigation measures. Research published by the Ada Lovelace Institute in December 2025, based on a nationally representative poll, found that 89% of the UK public support the establishment of an independent regulator for AI equipped with enforcement powers, and that 91% believe it is important that AI systems are developed and used in ways that treat people fairly. Critically, 84% of respondents feared that the government would prioritise its partnerships with large technology companies over the public interest when regulating AI. The Institute's UK Public Policy Lead, Nuala Polo, stated: "Our research is clear: there is a major misalignment between what the UK public want and what the government is offering in terms of AI regulation."
Sources: en.wikipedia.org
The relative molecular mass (denoted Mr) of a substance, formerly also called molecular weight and abbreviated as MW, is the mass of one molecule of that substance, relative to the dalton (Da), which is equal to 1/12 the mass of one atom of 12C. Due to this relativity, the molecular mass of a substance is commonly referred to as the relative molecular mass, and denoted to Mr.
α-Methylserotonin (αMS), also known as α-methyl-5-hydroxytryptamine (α-methyl-5-HT) or as 5-hydroxy-α-methyltryptamine (5-HO-αMT), is a tryptamine derivative closely related to the neurotransmitter serotonin (5-HT). It acts as a non-selective serotonin receptor agonist and has been used extensively in scientific research to study the function of the serotonin system.
=== Stability of naturally occurring nuclides === Most naturally occurring nuclides on earth are beta stable. Nuclides that are not beta stable have half-lives ranging from under a second to periods of time significantly greater than the age of the universe. One common example of a long-lived isotope is the odd-proton odd-neutron nuclide 4019K, which undergoes all three types of beta decay (β−, β+ and electron capture) with a half-life of 1.248×109 years.
Mast cell progenitors then enter the circulation and seed other tissues including the brain, heart, lung, peritoneal cavity, skin, and spleen, where they complete their maturation. eMPPs and HSCs start producing mature hematopoietic cells in the fetal liver around E12.5 and E14.5 respectively. HSCs are able to produce mast cells within a limited time window, declining after embryonic day E14.5. Whether mast cells originate mostly independent of HSCs, or "adult" mast cells originate in bone marrow (BM) from HSCs is debated. MC precursors of myeloid origin are found in bone marrow, but mature MCs are absent. Mast cells are easily generated from adult BM cells in vitro, but this has been less successful following HSC transplantation in vivo. It is unclear whether fetal-derived immune cells may be produced by HSCs during the fetal to neonatal period. In humans, the first yolk sac-derived MCs originate from mesodermal precursors that form in blood islands of the yolk sac, starting around three weeks into gestation. From there, circulating progenitors migrate into peripheral tissues for complete differentiation and maturation. Hematopoietic progenitors subsequently differentiate into multiple lineages, including erythroid, lymphoid, megakaryocytic, and myeloid precursors, which emerge in the fetal liver. Immature MCs are activated by antigens and cytokines and become specialized in response to their resident environment. MCs become widely distributed throughout all tissues including the brain.
His light bulbs are on display in the museum of the Château de Blois. In 1859, Moses G. Farmer built an electric incandescent light bulb using a platinum filament. Thomas Edison later saw one of these bulbs in a shop in Boston, Massachusetts, and asked Farmer for advice on the electric light business.
Sources: en.wikipedia.org
When journalists investigated this business connection, they also discovered that since the events of the protests in 2021, Urquía Carreño's construction company, SME Edificia, had on three separate occasions been subjected to intense and tedious investigations for alleged misconduct and malpractice by agents of the State Security Unit. It was also discovered that State Security agents told Urquía Carreño that if he complied with their wishes, they would leave his company alone. On February 22, 2024, only 48 hours after the first trial, the Supreme Court of Masonic Justice officially expelled Viñas Alonso from the Grand Lodge of Cuba and from the brotherhood of Freemasonry for a total of seven years. Viñas Alonso was given very short notice and could attend the trial, and Second Chamber President Brindisi Limonta was not informed of the proceedings. The Supreme Court's expulsion decision outcome document was not adorned with any signatures or any official seals. Brindisi Limonta expressed his displeasure that he was not invited to the oral hearing, and noted that this "oral hearing" did not even take place in the courthouse on the tenth floor of the National Masonic Temple, and most likely further violated the separation of powers because it was held in Urquía Carreño's office on the eleventh floor, the same office that was supposed to be under investigation by the police for the initial theft. Later that day, on February 22, Valdés García disbarred Brindisi Limonta as a magistrate of the Supreme Court of Masonic Justice.
===== Factors ===== There are many factors that can go into what makes an applicant more or less competitive. According to a survey of residency program directors by the NRMP in 2020, the following five factors were mentioned by directors over 75% of the time as having the most impact:
In the flaxseed variety Linum usitatissimum, a precursor peptide was found using Blast searching that potentially contains five core peptides separated by putative recognition sequences. Proteusins are named after "Proteus", a Greek shape-shifting sea god. Until now, the only known members in the family of Proteusins are called polytheonamides. They were originally presumed to be nonribosomal natural products due to the presence of many D-amino acids and other non-proteinogenic amino acids. However, a metagenomic study revealed the natural products as the most extensively modified class of RiPPs known to date. Six enzymes are responsible for installing a total of 48 posttranslational modifications onto the polytheonamide A and B precursor peptides, including 18 epimerizations. Polytheonamides are exceptionally large, as a single molecule is able to span a cell membrane and form an ion channel. Sactipeptides contain intramolecular linkages between the sulfur of Cys residues and the α-carbon of another residue in the peptide. A number of nonribosomal peptides bear the same modification. In 2003, the first RiPP with a sulfur-to-α-carbon linkage was reported when the structure of subtilosin A was determined using isotopically enriched media and NMR spectroscopy.
Cardiac muscle tissue or myocardium forms the bulk of the heart. The heart wall is a three-layered structure with a thick layer of myocardium sandwiched between the inner endocardium and the outer epicardium (also known as the visceral pericardium). The inner endocardium lines the cardiac chambers, covers the cardiac valves, and joins with the endothelium that lines the blood vessels that connect to the heart. On the outer aspect of the myocardium is the epicardium which forms part of the pericardial sac that surrounds, protects, and lubricates the heart. Within the myocardium, there are several sheets of cardiac muscle cells or cardiomyocytes. The sheets of muscle that wrap around the left ventricle closest to the endocardium are oriented perpendicularly to those closest to the epicardium. When these sheets contract in a coordinated manner they allow the ventricle to squeeze in several directions simultaneously – longitudinally (becoming shorter from apex to base), radially (becoming narrower from side to side), and with a twisting motion (similar to wringing out a damp cloth) to squeeze the maximum possible amount of blood out of the heart with each heartbeat. Contracting heart muscle uses a lot of energy, and therefore requires a constant flow of blood to provide oxygen and nutrients. Blood is brought to the myocardium by the coronary arteries. These originate from the aortic root and lie on the outer or epicardial surface of the heart. Blood is then drained away by the coronary veins into the right atrium.
Propranolol is occasionally used to treat performance anxiety, although evidence to support its use in any anxiety disorders is poor. Its efficacy in managing panic disorder appears similar to benzodiazepines, while carrying lower risks for addiction or abuse. Although beta blockers such as propranolol have been suggested to be beneficial in managing physical symptoms of anxiety, its efficacy in treating generalized anxiety disorder and panic disorder remain unestablished. It is thought that beta blockers do not directly treat psychological symptoms of anxiety, but can help control physical symptoms such as palpitations and tremors. This may interfere with a positive feedback loop to indirectly reduce psychological anxiety. A 2025 systematic review and meta-analysis found widespread prescription of beta blockers, namely propranolol, for treatment of anxiety disorders, but found no evidence of a beneficial effect relative to placebo or benzodiazepines in people with social phobia or panic disorder. However, the quality of evidence, including both numbers of studies and patients as well as quality and risk of bias of those studies, was limited. Findings were similar in a previous 2016 systematic review and meta-analysis. Other beta blockers that have been used to treat anxiety disorders besides propranolol include atenolol, betaxolol, nadolol, oxprenolol, and pindolol. Some experimentation has been conducted in other psychiatric areas:
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.